Back to search

National and Kapodistrian University of Athens

Παραγωγή κυτταροτοξικών κυττάρων γενετικά τροποποιημένων ώστε να αναγνωρίζουν την HER-2/neu ογκοπρωτεΐνη, μέσω χιμαιρικών υποδοχέων: Πειραματικά μοντέλα θεραπείας HER-2/neu θετικών χειρουργημένων όγκων

Abstract

dc:description

The HER-2/neu proto-oncogene is overexpressed in a variety of human cancers and this is correlated with increased malignancy and poor prognosis. HER-2/neu is an immunogenic protein because it contains epitopes which are recognized by T cells in a MHC class I and class II restricted fashion. However vaccination with most of these peptide-epitopes has met limited success mostly due to the fact that HER-2/neu is a self protein and as such is subjected to tolerance mechanisms which hamper the capacity of HER-2/neu high affinity T cell clones to develop effective HER-2/neu specific antitumor immunity. Another drawback for using peptides for vaccination studies is that these are limited only to patients expressing the appropriate MHC class I and class II alleles. To circumvent this problem, NK cells have been generated with a grafted MHC-independent recognition specificity for HER-2/neu expressing tumor cells. In contrast with T cells, NK cells don’t need a pre-sensitization to kill their target cells. NK cells can kill cancer cells in a MHC independent fashion, by cytokine production and tumor cell lysis. In addition NK cells are much more cytotoxic than T cells. However, T cells are used in the most immunotherapy protocols, because it is possible activated NK cells to be cytotoxic against healthy self cells or allergenic cells. Besides activated NK cells have such a low growth rate that it is difficult to be used in an immunotherapy protocol. To circumvent this problem, instead of NK cells, cells of NK92 cell line are used in immunotherapy protocols. In the present study, NK92 cells, transduced to express the scFv from a human anti-HER-2/neu monoclonal antibody fused to the ζ signaling domain of CD3, specifically lyse in vitro and in vivo HER-2/neu positive tumors. NK92 trunsduced cells directly mediated HER-2/neu targeted lysis of HER-2/neu expressing tumor cell lines, through a cell to cell contact. More importantly, NK92 genetically engineered cells mediated additional antitumor effects via secretion of the scFv domain of their chimeric receptor. The soluble scFv has a cytostatic activity against positive and dependant HER-2/neu cell lines (SKBR3). So, the NK92 transduced cells have a double mode of action against positive and dependant HER-2/neu cancer cells cancel.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Demirtzoglou, Fillio
  • Δεμιρτζόγλου, Τριανταφυλλιά

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/20001

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Demirtzoglou, Fillio; Δεμιρτζόγλου, Τριανταφυλλιά. Παραγωγή κυτταροτοξικών κυττάρων γενετικά τροποποιημένων ώστε να αναγνωρίζουν την HER-2/neu ογκοπρωτεΐνη, μέσω χιμαιρικών υποδοχέων: Πειραματικά μοντέλα θεραπείας HER-2/neu θετικών χειρουργημένων όγκων. National and Kapodistrian University of Athens, 2007. http://hdl.handle.net/10442/hedi/20001